Health-care companies fell after an earnings warning from one major biotech concern.
Biogen shares tumbled after it warned that competition from generic versions of its own medications could continue to cause revenue declines.
Merck shares fell after a late-stage study of its blockbuster cancer drug, Keytruda, missed its primary endpoint in patients with a kind of head-and-neck cancer.
Abbott Laboratories, maker of popular at-home antigen tests, raised its earnings projection for the year, boosted by higher-than-forecast revenue from Covid-19 testing products. Shares of Abbott fell.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
07-20-22 1726ET
